This website uses own and third party cookies to give you the best experience when you visit our website. By continuing to use this website, you consent to our use of these cookies.

Accept More information




Publications<< Back

Diaz-Ricart M, Escolar G

Vorapaxar for the reduction of atherothrombotic events.

Drugs Today. 2014 Nov;50(11):747-56, PMID: 25525635

Vorapaxar is a novel platelet inhibitor that potently and selectively inhibits thrombin-mediated platelet activation without interfering with thrombin-mediated cleavage of fibrinogen via antagonism of the platelet proteinase-activated receptor PAR1. Vorapaxar is a non-peptide himbacine analogue that has been developed for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease.

PHARMACOLOGY & PHARMACY

An initiative of

Ministerio de Economía y Competitividad Fondo Europeo de Desarrollo Regional IMIM - Parc de Salut Mar